| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.0086 | 0.8 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | -0.0085 | 0.8 |
| mRNA | Salubrinal | GDSC1000 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | WH-4-023 | GDSC1000 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |